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Background. In response to liver injury, hepatic stellate cell (HSC) activation causes excessive liver fibrosis. Here we show that
activation of RSK and phosphorylation of C/EBPb on Thr217 in activated HSC is critical for the progression of liver fibrosis.
Methodology/Principal Findings. Chronic treatment with the hepatotoxin CCl4 induced severe liver fibrosis in C/EBPb
+/+
mice but not in mice expressing C/EBPb-Ala217, a non-phosphorylatable RSK-inhibitory transgene. C/EBPb-Ala217 was present
within the death receptor complex II, with active caspase 8, and induced apoptosis of activated HSC. The C/EBPb-Ala217
peptides directly stimulated caspase 8 activation in a cell-free system. C/EBPb
+/+ mice with CCl4-induced severe liver fibrosis,
while continuing on CCl4, were treated with a cell permeant RSK-inhibitory peptide for 4 or 8 weeks. The peptide inhibited RSK
activation, stimulating apoptosis of HSC, preventing progression and inducing regression of liver fibrosis. We found a similar
activation of RSK and phosphorylation of human C/EBPb on Thr266 (human phosphoacceptor) in activated HSC in patients with
severe liver fibrosis but not in normal livers, suggesting that this pathway may also be relevant in human liver fibrosis.
Conclusions/Significance. These data indicate that the RSK-C/EBPb phosphorylation pathway is critical for the development
of liver fibrosis and suggest a potential therapeutic target.
Citation: Buck M, Chojkier M (2007) A Ribosomal S-6 Kinase–Mediated Signal to C/EBP-b Is Critical for the Development of Liver Fibrosis. PLoS
ONE 2(12): e1372. doi:10.1371/journal.pone.0001372
INTRODUCTION
The annual worldwide mortality from liver cirrhosis is approxi-
mately 800,000 [1], and there is no available treatment [2].
Excessive tissue repair in chronic liver diseases induced by viral,
toxic, immunologic, and metabolic disorders [3], results in the
deposition of scar tissue and the development of cirrhosis [4].
Quiescent hepatic stellate cells (HSC) produce negligible amounts
of extracellular matrix proteins (ECM), but after their activation,
these cells develop a myofibroblastic phenotype, proliferate and
become the main contributors of ECM [5] [6]. This step is
required for the development of liver fibrosis and cirrhosis [7–9].
The mitogen-activated protein kinase (MAPK) pathway,
through the extracellular signal-regulated kinase (ERK1/2),
activates RSK [10–14], resulting in the phosphorylation of mouse
C/EBPb (NP_034013 XP_916631) on Thr217 (Thr266 in human
C/EBPb) [5] [10]. The RSK pathway may be critical for HSC
activation induced by liver injury, because expression of a
catalytically inactive mutant RSK [15], blocked proliferation
and survival of cultured HSC upon their activation by collagen
type 1 [10]. The RSK phosphoacceptor site in C/EBPb is
identical in mouse and human, it is evolutionarily conserved [5],
and essential for survival of activated HSC [10].
Here we show that activation of RSK and phosphorylation of C/
EBPb on Thr217 in activated HSC is critical for the progression of
liver fibrosis. Chronic exposure to the hepatotoxin CCl4 can induce
liver cirrhosis in humans, and it is a classical method of inducing
liver injury and fibrosis in mice [10] [16]. We used this model to
investigate the role of RSK and phosphorylation of C/EBPb on
Thr217 in liver fibrosis. The hepatotoxin CCl4 induced severe liver
fibrosis in C/EBPb
+/+ mice but not in mice expressing C/EBPb-
Ala217, a non-phosphorylatable RSK-inhibitory transgene. C/
EBPb-Ala217 was present within the death receptor complex II,
with active caspase 8, and induced apoptosis of activated HSC. C/
EBPb
+/+ mice with severe liver fibrosis induced by an 8-week CCl4
treatment, while continuing on CCl4, were treated with a cell
permeant RSK-inhibitory peptide for 4 or 8 weeks. The peptide
inhibited RSK activation, stimulating apoptosis of HSC, prevent-
ing progression and inducing regression of liver fibrosis compared
to control mice treated with CCl4. We found similar activation of
RSK and phosphorylation of human C/EBPb (NP_005185) on
Thr266 (identical human phosphoacceptor) in activated HSC in
the liver of patients with severe liver fibrosis. These data indicate
that the RSK-C/EBPb phosphorylation pathway is critical for the
development of liver fibrosis, and that inhibition of the RSK
pathway is a potential therapeutic strategy for the prevention and
treatment of liver cirrhosis.
RESULTS
Mice expressing the RSK-inhibitory C/EBPb-Ala217
transgene are resistant to hepatotoxin-induced liver
fibrosis
Given the important role of RSK in the activation of HSC [10],
we hypothesized that a RSK-inhibitory transgenic protein would
block phosphorylation of C/EBPb on Thr217, induce HSC
apoptosis and decrease liver fibrosis following chronic liver injury.
Because the chronic exposure to the hepatotoxin CCl4 can induce
liver cirrhosis in humans, and it is a classical method of inducing
liver injury and fibrosis in mice [10] [16], we analyzed whether it
induces liver cirrhosis in mice expressing the dominant negative,
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This mutation changes the phosphorylatable Thr217 to a
nonphosphorylatable Ala217 within the RSK phosphoacceptor
site of C/EBPb. These animals are developmentally normal, fertile
and have a normal life span [10], suggesting that the RSK-
inhibitory transgene is apparently not toxic.
After the thrice-weekly intraperitoneal administration of CCl4
for 12 weeks, we determined the degree of liver fibrosis in coded
samples. This is an extensive chronic exposure for mice and
comparable to established severe liver fibrosis in humans [17]. We
evaluated liver fibrosis employing the following methods: i)
microscopic morphology; ii) semi-quantitative METAVIR clinical
grading system; iii) collagen type 1 immunofluorescence; iv)
quantitative Sirius red collagen-binding assay; v) quantitative
hydroxyproline collagen content; vi) RT-PCR for collagen type 1
mRNA; vii) RT-PCR for a-smooth muscle actin (a-SMA) mRNA
(present in activated HSC); and viii) RT-PCR for transforming
growth factor (TGF-b) mRNA (a pro-fibrotic cytokine) [4] [7] [8].
Liver samples were stained with the classical Mallory’s
trichrome to identify collagen in the extracellular matrix. The
hepatic collagen pattern and content of C/EBPb
+/+ (wt) mice
treated with CCl4 for 12 weeks were similar to those of patients
with liver cirrhosis (Figure 1A) [4] [8]. We graded the coded liver
samples with the standard 0 to 4 METAVIR clinical system [18],
and found that after CCl4 treatment, all C/EBPb
+/+ mice had
severe liver fibrosis (grade 4; n: 12), while all C/EBPb-Ala217 mice
had minimal or no liver fibrosis (grade 0; n: 6; grade 1; n:6 )
(P,0.0001) (Figure 1A). In agreement with the findings with the
Mallory’s trichrome, the Sirius red collagen-binding stain also
demonstrated decreased liver fibrosis after CCl4 treatment in C/
EBPb-Ala217 mice (Figure 1B). Similarly, confocal scanning
microscopy with specific antibodies against collagen type 1 also
identify decreased liver fibrosis in C/EBPb-Ala217 mice, com-
pared to C/EBPb
+/+ mice, after CCl4 treatment (Figure S1).
Although the intra- and inter-observer variability in the semi-
quantitative analysis of liver fibrosis was low, we confirmed these
findings using quantitative analysis of liver fibrosis.
The quantitative analysis of liver collagen, the major extracel-
lular matrix protein in liver fibrosis [4], with the Sirius red
collagen-binding assay [19] (Figure 1C), demonstrated that C/
EBPb-Ala217 mice were refractory to the development of liver
fibrosis after chronic exposure to the hepatotoxin. The liver
Figure 1. Mice expressing the RSK-inhibitory C/EBPb-Ala217 transgene are refractory to the induction of liver fibrosis. C/EBPb
+/+ [wt], C/EBPb-
Ala217 and C/EBPb
2/2 [ko] mice received weekly IP injections of CCl4 or mineral oil (control) for 12 weeks as described in Methods. A. Representative
Mallory’s trichrome stain for liver fibrosis (in blue; arrowheads). All C/EBPb
+/+ (wt) mice (n: 12) developed severe liver fibrosis. The C/EBPb-Ala217 (n:
12; P,0.0001) and C/EBPb
2/2 [ko] (n:6 ;P,0.01) mice had either no fibrosis or only minimal liver fibrosis. B. Representative Sirius red
immunohistochemistry for collagen (in red; arrowhead). Marked increase in liver collagen in a cirrhotic pattern was observed in C/EBPb
+/+, but not in
C/EBPb-Ala 217 or C/EBPb
2/2 [ko], mice. C. Analysis of hepatic collagen content by the Sirius red collagen–binding assay, showed a ,2.5-fold
increase in C/EBPb
+/+ mice treated with CCl4 (n: 12), compared to C/EBPb-Ala217 mice treated with CCl4 (n: 12; P,0.001). C/EBPb
2/2 mice were also
refractory to the induction of liver fibrosis by CCl4 (n:6 ;P,0.01). D. Analysis of hepatic collagen content by the hydroxyproline assay, showed a ,2-
fold increase in C/EBPb
+/+ mice treated with CCl4 (n: 7), compared to C/EBPb-Ala217 mice treated with CCl4 (n:6 ;P,0.01). C/EBPb
2/2 mice were also
refractory to the induction of liver fibrosis by CCl4 (n:6 ;P,0.01).
doi:10.1371/journal.pone.0001372.g001
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C/EBPb
+/+ (wt) mice (P,0.001) while remaining unchanged in
C/EBPb-Ala217 mice (NS) (Figure 1C). Similarly, chronic
administration of CCl4 increased liver hydroxyproline collagen
content in C/EBPb
+/+ (wt) mice (P,0.01) while remaining
unchanged in C/EBPb-Ala217 mice (NS) (Figure 1D).
We have reported that by lacking the essential C/EBPb-
PhosphoThr217, C/EBPb2/2 HSC are also unable to survive
the activation signals [10]. Thus, we postulated that C/EBPb2/2
mice would be refractory to the induction of liver fibrosis. Indeed,
C/EBPb
2/2 (ko) mice had a lower fibrotic response than C/
EBPb
+/+ mice to the chronic treatment with CCl4 (P,0.01)
(Figure 1 A, B, C and D).
Further, the expression of the liver fibrogenic indicators such as
collagen a 1 type 1 mRNA (newly synthesized collagen) (NM_
007742 )(P,0.01), a-SMA mRNA (activated HSC) (NM_007392.2)
(P,0.05), and TGF-b mRNA (fibrogenic cytokine) (NM_009370.2)
(P,0.01), were induced by CCl4 treatment significantly more in C/
EBPb
+/+ mice than in C/EBPb-Ala217 mice as measured by RT-
PCR (Figure 2).
Figure 2. Mice expressing the RSK-inhibitory C/EBPb-Ala217 transgene are resistant to hepatotoxin-induced liver fibrogenesis. Mice were treated
withCCl4 orcontrolmineraloilfor12or16 weeksandRT-PCRwasperformedasdescribedin MaterialsandMethods.A.RT-PCRforcollagena1 type1 was
induced in C/EBPb
+/+ [wt] mice treated with CCl4 f o r1 2o r1 6w e e k s( P,0.01). Treatment of these animals after week 8 with the RSK-inhibitory peptide
while continuing the exposure to the hepatotoxin, as described in Materials and Methods blocked this increase at week 16 (P,0.05). Collagen a1t y p e1
was not increased in livers of C/EBPb-Ala217 mice at 12 or 16 weeks (P,0.01). B. RT-PCR for a-SMA was induced in C/EBPb
+/+ [wt] mice treated with CCl4
for12or16 weeks(P,0.05).Treatmentoftheseanimalsafterweek8withtheRSK-inhibitorypeptidewhilecontinuingtheexposuretothehepatotoxin,as
describedinMaterials and Methods blocked thisincreaseatweek16(P,0.05). a-SMAwas not increased in liversofC/EBPb-Ala217 mice at12or16 weeks
(P,0.05). C. RT-PCR for TGF-b was induced in C/EBPb
+/+ [wt] mice treated with CCl4 for 12 or 16 weeks (P,0.01). Treatment of these animals after week 8
with the RSK-inhibitory peptide while continuing the exposure to the hepatotoxin, as described in Materials and Methods, blocked this increase at week
16 (P,0.01). TGF-b was not increased in livers of C/EBPb-Ala217 mice at 12 or 16 weeks (P,0.01).
doi:10.1371/journal.pone.0001372.g002
RSK and Liver Fibrosis
PLoS ONE | www.plosone.org 3 December 2007 | Issue 12 | e1372In summary, blocking phosphorylation of C/EBPb-Thr217
through the inhibition of RSK activity with the C/EBPb-Ala217
transgene or by C/EBPb gene knock-out decreases the fibrotic
response of the liver to chronic injury.
Mice expressing the RSK-inhibitory C/EBPb-Ala217
transgene are resistant to hepatotoxin-induced liver
inflammation
Because liver inflammation, at least in part through the activation
of macrophages [20–22] and loss of hepato-trophic factors from
HSC and liver endothelial cells [23] [24] is a major contributor to
liver injury and liver fibrosis, we assessed the degree of liver injury
and inflammation in response to the hepatotoxin. Liver injury was
determined by measuring serum alanine aminotransferase (ALT)
levels in mice after exposure to the hepatotoxin. Serum ALT is a
sensitive and specific indicator of hepatocellular injury in humans
and animals, and it is the standard clinical test used by the U.S.
Food and Drug Administration to ascertain hepatotoxicity of
herbal products and drugs [25] [26]. We found that C/EBPb-
Ala217 mice had less liver injury than C/EBPb
+/+ mice after CCl4
treatment, judging by the ALT serum levels (Table S1).
Using a microarray assay to assess expression of 66 inflamma-
tion genes in the liver of control and transgenic mice, we found
that the expression of 21 inflammation genes was decreased,
while the expression of other 45 inflammation genes was
unchanged in C/EBPb-Ala217 mice after CCl4–induced liver
injury, when compared to C/EBPb
+/+ animals treated with CCl4
(Table 1).
These data suggest that partial resistance to liver injury and
inflammation may contribute to the prevention of liver fibrosis in C/
EBPb-Ala217 mice. A decreased inflammatory response, mediated at
least in part by monocytes/macrophages in the livers of C/EBPb
+/+
mice (Figure 3A), may be responsible for the decreased liver injury in
C/EBPb-Ala217 mice, since RSK inhibition also affected the
recruitment of CD-68+ inflammatory cells to the liver (Figure 3B).
Given that CCl4 is metabolized by the cythocrome-P-450 2E-
1(Cyp-2E-1) (ABH07947) to form a free radical hepatotoxic
metabolite [27], we evaluated the possibility that C/EBPb-Ala217
affects Cyp-2E1 expression and/or activity. The Cyp-2E1 mRNA
expression was similarly inhibited by CCl4 in the livers of C/EBPb
+/
+and C/EBPb-Ala217mice(FigureS2A).Inaddition,the Cyp-2E-1
protein expression was also similar in the livers of C/EBPb
+/+ and
C/EBPb-Ala217 mice after the hepatotoxin treatment (Figure S2B).
Moreover, the Cyp-2E1 activity as measured in a cell-free system
was unaltered by a RSK-inhibitory C/EBPb-Ala217 peptide, even
at mM concentrations (Figure S2C).
These results indicate that the protective effects of the RSK-
inhibitory transgene in CCl4 -induced liver injury and fibrosis are
not due to the spurious blockade of the production of a toxic CCl4
metabolite.
Mice expressing the RSK-inhibitory C/EBPb-Ala217
transgene are resistant to hepatotoxin-induced HSC
activation and proliferation
Quiescent HSC produce negligible amounts of ECM, but after
their activation, these cells develop a myofibroblastic phenotype,
Table 1. Decreased Inflammation in the Livers of C/EBPb- Ala217 mice after CCl4 treatment.
..................................................................................................................................................
# GeneBank Symbol Description Gene Name
Liver Expression in C/EBPb-
A 217 (% of control)
1 NM_009744 Bcl6 B-cell leukemia/lymphoma 6 Bcl5 16
2 NM_009807 Casp1 Caspase 1 ICE/IL 1bc 19
3 NM_011331 Ccl12 Chemokine (C-C motif) ligand 12 MCP-5/Scya12 32
4 NM_011888 Ccl19 Chemokine (C-C motif) ligand 19 CKb11/ELC 9
5 NM_021443 Ccl8 Chemokine (C-C motif) ligand 8 1810063B20Rik/AB023418 9
6 NM_011338 Ccl9 Chemokine (C-C motif) ligand 9 CCF18/MRP-2 27
7 NM_009915 Ccr2 Chemokine (C-C motif) receptor 2 CC-CKR-2/CCR2A 16
8 NM_009916 Ccr4 Chemokine (C-C motif) receptor 4 Cmkbr4/LESTR 23
9 NM_009142 Cx3cl1 Chemokine (C-X3-C motif) ligand 1 AB030188/ABCD-3 30
10 NM_021704 Cxcl12 Chemokine (C-X-C motif) ligand 12 AI174028/PBSF 11
11 NM_009141 Cxcl5 Chemokine (C-X-C motif) ligand 5 AMCF-II/ENA-78 23
12 NM_008599 Cxcl9 Chemokine (C-X-C motif) ligand 9 BB139920/CMK 9
13 NM_010548 IL10 Interleukin 10 CSIF/IL-10 23
14 NM_008349 IL10rb Interleukin 10 receptor, beta 6620401D04Rik/AI528744 29
15 NM_010551 IL16 Interleukin 16 mKIAA4048 30
16 NM_008360 IL18 Interleukin 18 Igif/IL-18 22
17 NM_010555 Il1r2 Interleukin 1 receptor, type II CD121b/IL1r-2 27
18 NM_008368 IL2rb Interleukin 2 receptor, beta chain CD122/IL-15Rbeta 32
19 NM_013563 IL2rg Interleukin 2 receptor, gamma chain CD132/[g]c 32
20 NM_009263 Spp1 Secreted phosphoprotein 1 AA960535/AI790405 7
21 NM_011798 Xcr1 Chemokine (C motif) receptor 1 Ccxcr1/GPR5 17
Animals received either mineral oil [MO] or CCl4. Thirty hours after a single intraperitoneal dose of CCl4,
C/EBPb Ala217 (n: 9) mice had a markedly decreased liver expression of inflammatory genes compared to C/EBPb
+/+ mice (n: 9). A panel of 86 inflammatory genes were
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PLoS ONE | www.plosone.org 4 December 2007 | Issue 12 | e1372proliferate, and become the main contributors of ECM [5] [6].
Because this step is required for the development of liver fibrosis
and cirrhosis [7–9], we analyzed the activation and proliferation of
HSC in the livers of mice chronically exposed to the hepatotoxin.
As expected, chronic CCl4 administration to C/EBPb
+/+ (wt)
mice, induced marked activation of HSC, as indicated by the
positive immunofluorescence for a-SMA within the scar tissue [5]
[6] (Figure 4A), and proliferation of HSC, as indicated by the
presence of proliferating cell nuclear antigen (PCNA; DNA poly-
merase d auxiliary protein), an S-phase marker [28] (Figure 4B).
By contrast, C/EBPb-Ala217 mice were refractory to the
induction of HSC activation and proliferation by CCl4 treatment
(Figure 4A and B). Moreover, chronic CCl4 treatment induced the
apoptotic cascade in HSC in the livers of C/EBPb-Ala217 mice,
but not C/EBPb
+/+ mice, as determined by the presence of active
caspase 3 immunofluorescence (Figure 4B). After chronic CCl4
administration, C/EBPb was phosphorylated on Thr217 in HSC
of C/EBPb
+/+ mice, but not in C/EBPb-Ala217 mice, as deter-
mined by confocal microscopy (Figure 4A and B), using specific
antibodies against this phosphorylated epitope [10].
Because the mixed cell population of the liver limits the
evaluation of signaling cascades in a specific cell type, we studied
the fibrogenic pathway in purified HSC. After chronic CCl4 or
control mineral oil administration, we analyzed proteins associated
Figure 3. Mice expressing the RSK-inhibitory C/EBPb-Ala217 trans-
gene are resistant to hepatotoxin-induced liver inflammation. Mice
were treated with CCl4 or control mineral oil for 16 weeks as described
in Materials and Methods. A. Activated monocytes/macrophages,
identified by confocal microscopy for CD-68 (green), were increased
in livers of C/EBPb
+/+ [wt] mice treated with CCl4 for 16 weeks (middle
panels). Treatment of these animals after week 8 with the RSK-inhibitory
peptide while continuing the exposure to the hepatotoxin, as described
in Material and methods, blocked the monocytes/macrophage inflam-
matory reaction at week 16 (lower panels). Nuclei are identified with
TO-PRO-3 (blue). Only background staining was observed when
omitting the first antibody. Microscopy shown is representative of six
animals in each group. B. Activated monocytes/macrophages, were not
increased in livers of C/EBPb-Ala217 mice as much as in the livers of C/
EBPb
+/+ [wt] mice after treatment with CCl4 for 16 weeks (lower panel).
Microscopy shown is representative of six animals in each group.
doi:10.1371/journal.pone.0001372.g003 Figure 4. Mice expressing the RSK-inhibitory C/EBPb-Ala217 trans-
gene are refractory to hepatic stellate cell activation and prolifer-
ation. Mice received CCl4 or mineral oil injections for 12 weeks as
described in Materials and methods. A. Activated stellate cells,
identified by confocal microscopy for a-smooth muscle actin (a-SMA;
red), displayed C/EBPb-PhosphoThr217 (green) in livers of C/EBPb
+/+
[wt], but not C/EBPb-Ala217, mice treated with CCl4. Colocalization of a-
SMA and C/EBPb-PhosphoThr217 is shown in yellow (merge). Nuclei are
identified with TO-PRO-3 (blue). Only background staining was
observed when omitting the first antibody. B. Proliferating cell nuclear
antigen (PCNA; red) was present in activated stellate cells only in livers
of C/EBPb
+/+ [wt] mice treated with CCl4, while active caspase 3 (green)
was found in HSC only in livers of C/EBPb-Ala217 mice treated with
CCl4. Nuclei are identified with TO-PRO-3 (blue).
doi:10.1371/journal.pone.0001372.g004
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C/EBPb
+/+ and C/EBPb-Ala217 mice. C/EBPb-Ala217 binding
to, and blocking, RSK phosphorylation (Figure 5A) results in
decreased phosphorylation of C/EBPb on Thr217, and presum-
ably, other target survival proteins by activated RSK [5][10][11].
The Ac-KAla217VD-CHO or C/EBPb216-253-Ala217 (0.25 nM)
peptides inhibited RSK activity in a cell-free system, suggesting a
directeffect (Figure 5B). The Ac-KThr217VD-CHO wt peptide also
inhibited RSK, probably, because it binds to the kinase but cannot
be phosphorylated by RSK given its small size (Figure 5B).
C/EBPb-Ala217 transgene and unphosphorylated
C/EBPb-Thr217 are associated with active caspase 8
and death receptor complex II proteins in HSC
Unexpectedly, we found that C/EBPb-Ala217 was present with
active caspase 8 in HSC from C/EBPb-Ala217 mice after chronic
CCl4 administration and, to a lesser extent, after mineral oil
administration (Figure 6A). In contrast, the association between
inactive procaspase 8 and C/EBPb-PhosphoThr217 (Figure 6A),
as well as that between C/EBPb and activated phospho-RSK
(Figure 5A), increased in HSC of C/EBPb
+/+ mice after chronic
CCl4 administration. Reciprocal immunoprecipitation with cas-
pase 8 antibodies confirmed the presence of C/EBPb- Ala217 with
active caspase 8 (Figure 6A). RSK phosphorylation was inhibited
in HSC from C/EBPb-Ala217 mice, indicating that C/EBPb-
Ala217 not only associates with RSK but that it also decreases its
phosphorylation and activation (Figure 5A). The hypothesis that
inhibition of RSK by nonphosphorylatable C/EBPb-Ala217 is
critical for caspase 8 activation is supported by the increased
caspase 8 activation in HSC from C/EBPb-Ala217 mice after
chronic CCl4 administration (Figure 6A).
Next, we studied whether blocking RSK activity results in
activation of caspase 8. Activated primary human C/EBPb
+/+ HSC
were transfected with vectors expressing green fluorescent protein
with a control wt RSK (GFP), to facilitate cell sorting, with a
dominant negative RSK mutant, or with the RSK-inhibitory
dominant negative C/EBPb-Ala217. The HSC were activated on
a collagen type 1 matrix, a condition that recapitulates the activation
of HSC in vivo [9], and identified by their expression of GFAP [10].
Figure 5. C/EBPb-Ala217 inhibits RSK activation in hepatic stellate cells. A. A phospho-RSK immunoblot was performed on RSK
immunoprecipitates from protein lysates of purified HSC in an experiment conducted as described in (Fig. 1). Phosphorylated RSK (RSKp380) was
decreased in HSC isolated from C/EBPb-Ala217 mice. C/EBPb and RSK were similar in the different experimental groups. b-Actin was used as an
internal control for the immunoprecipitations. Results from triplicate samples of three independent experiments are shown. B. RSK activity was
determined in a cell-free system as described in Methods. Recombinant RSK was activated with ATP (125 mM) in the presence or absence of Ac-
KThrVD-CHO (200 mM), Ac-KAlaVD-CHO (200 mM), or C/EBPb216-253-Ala217 (0.25 nM) peptides. Staurosporine was used as a control inhibitor (0.01
nM). All C/EBPb peptides inhibited RSK activity to a similar extent as staurosporine (P,0.01). Results from triplicate samples of two independent
experiments are shown. C. Primary human C/EBPb
+/+ HSC were transfected with vectors (1 mg each) expressing green fluorescent protein with
control wt RSK (GFP), a dominant negative RSK mutant, or C/EBPb-Ala217. Transfected HSC were selected by sorting for GFP, and cell lysates were
immunoprecipitated with C/EBPb specific antibodies. C/EBPb-PhosphoThr217 (C/EBPbp217), and caspase 8 immunoblots were performed in C/EBPb
immunoprecipitates. Dominant negative RSK or C/EPBb-Ala217 prevented C/EPBb phosphorylation and stimulated the association of
unphosphorylated C/EBPb with active caspase 8. b-Actin was used as an internal control for the immunoprecipitations. Results from triplicate
samples of three independent experiments are shown.
doi:10.1371/journal.pone.0001372.g005
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phosphoacceptor Thr217) was markedly decreased in activated
human HSC expressing either the RSK mutant or C/EBPb-
Ala217. Moreover, we found that unphosphorylated C/EBPb was
associated active caspase 8 (Figure 5C). The RSK phosphoaccep-
tor site in C/EBPb is identical in mouse and human, it is
evolutionarily conserved [5], and essential for HSC survival upon
their activation [10].
C/EBPb-Ala266 associated with active caspase 8, in cells
expressing the dominant negative RSK (Figure 5C), which prevents
C/EBPb phosphorylation on Thr266 by RSK. In contrast, in the
control cells expressing GFP and RSK wt, C/EBPb was
phosphorylated and associated with procaspase 8 (Figure 5C), as
we reported previously [10]. Reciprocal immunoprecipitation with
caspase 8 specific antibodies confirmed the presence of unpho-
sphorylated C/EBPb with active caspase 8 (Figure 6 B and C). After
Figure 6. C/EBPb-Ala217 associates with active caspase 8 in hepatic stellate cells. A. A caspase 8 immunoblot was performed on C/EBPb
immunoprecipitates from protein lysates from samples described in (Fig 5 A). The association between C/EBPb-Ala217 with active caspase 8 was
increased in HSC isolated from C/EBPb-Ala217 mice. Phosphorylated C/EBPb-Thr217 was decreased in HSC from C/EBPb-Ala217 mice treated with
CCl4. C/EBPb and RSK were similar in the different experimental groups. b-Actin was used as an internal control for the immunoprecipitations. B.
Reciprocal caspase 8 immunoprecipitation of experiment described in (A) confirmed the association of C/EBPb-Ala217 with active caspase 8. b-Actin
was used as an internal control for the immunoprecipitations. C. Reciprocal caspase 8 immunoprecipitation of experiment described in (Figure 5C),
confirmed the association of C/EBPb-Ala217 with active caspase 8. b-Actin was used as an internal control for the immunoprecipitations.
doi:10.1371/journal.pone.0001372.g006
RSK and Liver Fibrosis
PLoS ONE | www.plosone.org 7 December 2007 | Issue 12 | e1372blocking the RSK-C/EBPb phosphorylation cascade in activated
HSC, with either an ERK1/2 inhibitor or a cell permeant Ac-
KAla217VD-CHO peptide, which contains the mutated C/EBPb-
Ala217 phosphoacceptor, unphosphorylated C/EBPb became
associated with other members of the death receptor complex II,
such as TNFR1, TRAF2, TRADD and RIP [29] (Figure 7A, B, and
C).These associations were identified inC/EBPb,TNFR1,TRAF2,
TRADD and RIP immunoprecipitations (Figure 7 and Figure S3).
The Ac-KAla217VD-CHO peptide is cell permeant due to its N-
terminus acetyl group, as it has been documented for other peptides
used as substrate or inhibitors of caspases [30] [31].
A cell-permeant C/EBPb-Ala217 peptide stimulates
active caspase 8 and cell death in collagen type 1-
induced activation of cultured HSC
We corroborated the activation of caspase 8 in HSC, under
conditions that prevented phosphorylation of C/EBPb,a s
described above, by demonstrating the association between
cytochrome C with Apaf-1 (Figure 7D), which reflects a
downstream amplification effect of active caspase 8 on mitochon-
drial apoptotic pathways [32]. The reciprocal analysis could not be
performed since Apaf-1 antibodies are not suitable for immuno-
Figure 7. RSK inhibition induces the association of C/EBPb with active caspase 8, TNFR1, TRAF2, TRADD and RIP. A. TRADD, C/EBPb, RIP and
caspase 8 immunoblots were performed on C/EBPb immunoprecipitates from primary human HSC treated with an ERK1/2 inhibitor (10 mM) or the
cell permeant Ac-KA217VD-CHO peptide (200 mM). Blocking the phosphorylation of C/EBPb by RSK with the ERK1/2 inhibitor or the cell permeant Ac-
KA217VD-CHO (KAVD) peptide, increased the association between C/EBPb, active caspase 8, TRADD and RIP. b-Actin was used as an internal control
for the immunoprecipitations. B. TNFR1 and C/EBPb immunoblots were performed on C/EBPb immunoprecipitates from HSC isolated from mice
treated with CCl4 for 12 or 16 weeks as described in Materials and Methods. Blocking the phosphorylation of C/EBPb by RSK with C/EBPb-Ala217
transgene or the cell permeant Ac-KA217VD-CHO peptide increased the association between C/EBPb and TNFR1. b-Actin was used as an internal
control for the immunoprecipitations. C. TRAF2 and C/EBPb immunoblots were performed on C/EBPb immunoprecipitates from HSC isolated from
mice treated with CCl4 for 12 or 16 weeks as described in Materials and Methods. Blocking the phosphorylation of C/EBPb by RSK with C/EBPb-Ala217
transgene or the cell permeant Ac-KA217VD-CHO peptide increased the association between C/EBPb and TRAF2. b-Actin was used as an internal
control for the immunoprecipitations. D. Cytochrome C and Apaf1 immunoblots were performed on cytochrome C immunoprecipitates in livers from
mice treated with CCl4 for 12 or 16 weeks as described in Materials and Methods. Blocking the phosphorylation of C/EBPb by RSK with C/EBPb-Ala217
transgene or the cell permeant Ac-KA217VD-CHO peptide increased the association between cytochrome C and Apaf1. b-Actin was used as an
internal control for the immunoprecipitations.
doi:10.1371/journal.pone.0001372.g007
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phorylation cascade with the cell permeant C/EBPb-Ala217
peptide, Ac-KAla217VD-CHO induced expression of the apo-
ptosis effector caspase 3 in cultured, activated mouse HSC, but not
in primary mouse hepatocytes (Figure S4). These findings suggest
a selective induction of apoptotic pathways by C/EBPb-Ala217
peptides in cultured activated HSC but not in cultured primary
hepatocytes. This conclusion is supported by the apoptotic
changes in activated HSC but not hepatocytes of C/EBPb-
Ala217 transgenic mice treated with CCl4, and by the lack of
apoptosis of normal quiescent HSC and hepatocytes of C/EBPb-
Ala217 transgenic mice not treated with CCl4. In addition, after
CCl4 treatment, hepatocyte injury and hepatic inflammation are
decreased in C/EBPb-Ala217 transgenic mice compared to
control C/EBPb
+/+ mice, arguing for a protective rather than
an apoptotic effect on hepatocytes.
Our findings in cell-free, cellular and animal models strongly
support the main hypothesis, and suggest a novel, physiological
role for unphosphorylated C/EBPb on caspase 8 activation.
Indeed, we found that caspase 8 activation is stimulated by C/
EBPb-Ala217 in HSC from C/EBPb-Ala217 mice treated with
CCl4 (Figure 8A). In addition, we determined that the peptide
enhanced the activity of recombinant caspase 8 in a cell-free
system at picomolar concentrations (Figure 8B). To our knowl-
edge, the C/EBPb-Ala217 peptides are the first reported
compounds to directly enhance caspase 8 activation (G Salvesen,
personal communication).
These experiments provided a strong proof-of-principle that
RSK activation mediates the signaling required for liver
inflammation and liver fibrosis.
A cell-permeant C/EBPb-Ala217 peptide stimulates
cell death in hepatotoxin-induced activation of
HSC
Because in preliminary studies the cell permeant tetrapeptide Ac-
KAla217VD-CHO was effective in inducing apoptosis of cultured
activated HSC [10], we studied whether this peptide would also be
effective in inducing apoptosis of activated HSC in a physiolog-
ically relevant animal model of liver injury [10] [16]. To activate
HSC, we administered a single dose of CCl4 to C/EBPb
+/+ (wt)
mice, while control mice received the mineral oil vehicle [16]. Six
hours later, animals received an intraperitoneal injection of the cell
permeant Ac-KAla217VD-CHO peptide [10] (100 mg) or saline
vehicle (100 ml). In preliminary studies, we found that 1–100 mgo f
peptide dose provided adequate bioavailability (M B, unpublished
observations). Animals were sacrificed at 24 h. Acute CCl4
administration induced both activation and proliferation of
HSC (among other hepatic cells), judging by the expression of
aSMA and PCNA, as determined by confocal microscopy
(Figure 8C and D).
HSC activation and proliferation were blocked by
treatment with the Ac-KAla217VD-CHO peptide, but not by
treatment with saline (Figure 8C and D). Similarly to our
findings of RSK inhibition in cell-free, cultured primary stellate
cells and in C/EBPb-Ala217 transgenic mice, the Ac-KA-
la217VD-CHO peptide prevented the phosphorylation of
C/EBPb on Thr217 in HSC activated by the liver injury induced
by CCl4 (Figure 8C). Further, and in agreement to our findings of
the increased caspase 8 activation in cell-free, cultured primary
stellate cells and in C/EBPb-A217 transgenic mice, the Ac-
KAla217VD-CHO peptide stimulated the apoptotic pathway of
C/EBPb wt HSC as indicated by the presence of active caspase 3
(Figure 8 D).
A cell-permeant C/EBPb-Ala217 peptide inhibits
progression and stimulates regression of
hepatotoxin-induced liver fibrosis
Activation of stellate cells is responsible for the development of
liver fibrosis in chronic liver diseases of all causes [3][4] [8], and
remarkably, HSC clearance by apoptosis may allow recovery from
liver injury and reversal of liver fibrosis [33] [34].
Given the effective blocking by the RSK-inhibitory peptide of
molecular pathways leading to liver fibrosis in an acute CCl4
model of liver injury and fibrogenesis, we asked whether these
effects would occur in a model of established liver fibrosis due to
chronic liver injury, reproducing the disease state of patients with
severe liver injury and fibrosis.
Therefore, C/EBPb
+/+ mice with severe liver fibrosis, after
receiving CCl4 for 8 weeks, were treated with the RSK inhibitory
peptide for an additional 4 or 8 weeks (5 mg IP, three times/week,
for week 9, followed by 1 mg IP, three times/week for weeks 10–12
or 10–16), while continuing to induce liver injury and fibrosis with
CCl4. Treatment of animals with liver fibrosis with the peptide,
while continuing to receive CCl4, prevented the progression and
induced regression of liver fibrosis compared to control mice
treated with CCl4. At week-12 or week-16, there was a marked
regression of liver fibrosis judging by the trichrome stain
(Figure 8E) and Sirius red staining (Figure S5). All control mice
(n: 22) had severe liver fibrosis, while all mice that received the
RSK-inhibitory peptide had minimal or no liver fibrosis. We
confirmed these findings by quantitative analysis of liver collagen
with the Sirius red binding assay (P,0.01) [19] (Figure 8F).
Analysis of hepatic collagen content by the hydroxyproline assay
(Figure 8G), showed a 2.2-, 3.5-, and 5.3-fold increase in C/
EBPb
+/+ mice treated with CCl4 for 8, 12 and 16 weeks,
respectively (n: 8 for 8 weeks; n: 7 for 12 weeks and n: 7 for the
16 weeks), compared to animals treated with the RSK-inhibitory
peptide (n: 6 for 12 weeks; n: 8 for 16 weeks; P,0.01).
In agreement with the results observed after CCl4 treatment in
mice expressing the C/EBPb-Ala217 transgene, treatment with
the RSK-inhibitory peptide of C/EBPb
+/+ mice with severe liver
fibrosis induced by CCl4, while continuing to receive CCl4,
reduced the following: i) expression of liver fibrogenic indicators
such as collagen a 1 type 1 mRNA (P,0.05), a-SMA mRNA
(activated HSC) (P,0.05), and TGF-b mRNA (fibrogenic
cytokine) (P,0.01) (Figure 2A, B, and C); and ii) recruitment of
CD-68+ inflammatory cells to the liver (Figure 3A).
Increased expression of active RSK and C/EBPb-
PhosphoThr266 in activated HSC of human liver
fibrosis
The RSK phosphoacceptor site in C/EBPb is identical in mouse
and human, it is evolutionarily conserved [5], and necessary for
HSC survival upon their activation [10]. The RSK pathway may
be critical for HSC activation induced by liver injury, because
expression of a catalytically inactive mutant RSK [15], blocked
proliferation and survival of cultured HSC upon their activation
by collagen type 1 [10].
To assess the relevance to human liver fibrosis of the cellular
and animal models of liver fibrosis, we analyzed, in preliminary
studies, the role of activated RSK and phosphorylated C/EBPb on
Thr266 (identical to mouse Thr217 phosphoacceptor) as possible
mechanisms leading to increased liver fibrosis in four patients with
chronic hepatitis C viral infection that resulted in severe liver
fibrosis (53617 years) (see Materials and methods). Liver biopsies
from hepatitis C patients afflicted with severe liver fibrosis
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both active, phosphorylated RSK and phosphorylated human C/
EBPb on Thr266 in activated HSC within the fibrous tissue,
compared with samples from three control patients (60613 years)
as identified by confocal scanning microscopy with specific
antibodies against RSK-PhosphoSer380, C/EBPb-Phos-
phoThr266, and glial fibrillary protein for HSC [10] (Figure 9 A
and B).
Figure 8. The RSK-inhibitory peptide blocks hepatic stellate cell activation and liver fibrosis induced by CCl4.ACaspase 8 activity was measured
in lysates from HSC isolated from C/EBPb
+/+ [wt] and C/EBPb-Ala217 mice untreated or treated with CCl4 for 24 hr. Caspase activity was increased in
C/EBPb-Ala217 mice treated with CCl4. Results from triplicate samples of two independent experiments are shown. B. Caspase activation in a cell-free
system was determined as described in Methods. The Ac-KAla217VD-CHO peptide enhanced the activation of caspase 8 at picomolar concentrations.
Baseline caspase 8 activity was 3.8 U (100%). Results from triplicate samples of three independent experiments are shown (P,0.01 for the Ac-
KAla217VD-CHO peptide). C. Animals received a single injection of CCl4 or mineral oil as described in Methods. a-SMA (red) and C/EBPb-
PhosphoThr217 (green) were identified as described in Materials and methods. Treatment with the cell permeant Ac-KAla217VD-CHO peptide
blocked the expression of a-SMA and C/EBPb-PhosphoThr217. D. PCNA (red) and active caspase 3 (green) were identified as described in Materials
and methods. Treatment with the Ac-KAla217VD–CHO peptide blocked the expression of PCNA and induced active caspase 3. E. C/EBPb
+/+ (wt) mice
with severe liver fibrosis after treatment with CCl4 for 8 weeks, while continuing on CCl4, received the RSK inhibitory peptide (5 mg IP, three times/
week, for week 9 followed by 1 mg IP, three times/week for weeks 10–12 or 10–16). These are representative Mallory’s trichrome stain for liver fibrosis
(in blue). All control mice (n: 8 at 8-weeks; n: 8 at 12-weeks; and n: 8 at 16-weeks) developed severe liver fibrosis, while mice receiving the RSK-inbitory
peptide (n: 8 at 12-weeks; and n: 8 at 16-weeks) had no fibrosis or only minimal liver fibrosis (P,0.01). F. Analysis of hepatic collagen content by the
Sirius red collagen–binding assay showed a ,2.5 to 3-fold increase in C/EBPb
+/+ mice treated with CCl4 (n: 8 for 8 weeks; n: 8 for 12 weeks and n: 8 for
the 16 weeks), compared to animals also receiving the RSK-inbitory peptide (n: 6 for 12weeks; n: 8 for 16 weeks; P,0.01). G. Analysis of hepatic
collagen content by the hydroxyproline assay, showed a 2.2-, 3.5- and 5.3-fold increase in C/EBPb
+/+ mice treated with CCl4, respectively (n: 8 for
8 weeks; n: 7 for 12 weeks and n: 7 for the 16 weeks), compared to animals also receiving the RSK-inbitory peptide (n: 6 for 12weeks; n: 8 for
16 weeks; P,0.01).
doi:10.1371/journal.pone.0001372.g008
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fibrosis are congruent with the hypothesis we developed in cell-
free, cellular and animal models that RSK activation and its
phosphorylation of C/EBPb in activated HSC may be important
in the development of human liver fibrosis.
DISCUSSION
Activation of HSC is responsible for the development of liver
fibrosis in chronic liver diseases of all causes [3] [4] [8], and
remarkably, HSC clearance by apoptosis may allow recovery from
liver injury and reversal of liver fibrosis [33] [34].
In this study we show that activation of RSK and phosphor-
ylation of C/EBPb on Thr217 in activated HSC is critical for the
progression of liver fibrosis. We used the classical CCl4-induced
liver injury and fibrosis model in mice [10] [16], primary mouse
and human HSC [10], and cell-free systems to investigate the role
of RSK and phosphorylation of C/EBPb on Thr217 in the
activation of HSC and liver fibrosis. It would be important to
determine whether RSK and phosphorylation of C/EBPb are also
critical in other animal models that reflect other causes of human
liver fibrosis, such as biliary cirrhosis, alcoholic liver disease,
immune liver injury and genetic iron overload [3]. Any one of
these studies will require as extensive an analysis as that performed
with the CCl4 model of liver fibrosis.
We found that mice expressing the RSK-inhibitory C/EBPb-
Ala217 transgene were refractory to the induction of HSC
activation and proliferation by CCl4 treatment. After chronic
CCl4 administration, C/EBPb was phosphorylated on Thr217 in
HSC of C/EBPb
+/+ mice, but not of C/EBPb-Ala217 mice. C/
EBPb-Ala217 binding to, and blocking, RSK phosphorylation
results in decreased phosphorylation of C/EBPb on Thr217, and
presumably, other target survival proteins by activated RSK.
Moreover, chronic CCl4 treatment induced the apoptotic cascade
in HSC in the livers of C/EBPb-Ala217 mice, but not C/EBPb
+/+
mice, as determined by the presence of active caspase 8 and 3.
C/EBPb-Ala217 was present within the death receptor complex
II, with active caspase 8, and was linked to apoptosis of activated
HSC, freshly isolated from transgenic mice. After blocking the
RSK-C/EBPb phosphorylation cascade in activated human HSC
in culture, with either an ERK1/2 inhibitor or a cell permeant
RSK-inhibitory peptide, Ac-KAla217VD-CHO, unphosphory-
lated C/EBPb became associated with other members of the
death receptor complex II, such as TNFR1, TRAF2, TRADD
and RIP [29]. The combined results suggest a functional link
between inactive RSK and the active caspase 8 complex II.
Further, inactive RSK and active caspase 8 are co-immunopre-
cipitated with C/EBPb-Ala217 or unphosphorylated C/EBPb,
suggesting also a physical link. However, identification of a
putative RSK/caspase 8 complex would require crystallographic
analysis.
In support of our proposed role of unphosphorylated and
phosphorylated C/EBPb-Thr217 on the modulation of HSC
survival following their activation by liver injury, expression of the
dominant positive phosphorylation mimic C/EBPb-Glu217 [5]
enhances survival of cultured progenitor neuronal cells [35] while
C/EBPb
2/2 macrophages display defective bacterial killing and
tumor cytotoxicity [36]. A corollary of our study is that mice
expressing the C/EBPb-Glu217 transgene would be more
susceptible to HSC activation and liver fibrosis induced by liver
injury and inflammation. Indeed, this seems to be the case in
preliminary studies with these novel transgenic mice (M.B,
unpublished observations).
Although the association between C/EBPb-PhosphoThr217
and inactive procaspase 8 is linked to the inhibition of active
caspase 8 [10], the precise molecular mechanisms by which
phosphorylated C/EBPb prevents liver injury-induced HSC
apoptosis have not been characterized yet. Phosphorylated C/
EBPb could induce the inhibition of pro-apoptotic proteins, such
as p53 [37] or the activation of survival proteins, such as MnSOD
[38], or FLIP [29]. Alternatively, granzyme B rather than caspase
8 could be the major target of phosphorylated C/EBPb-Thr217,
as we suggested previously for HSC apoptosis/survival [10].
The hepatotoxin CCl4 induced severe liver fibrosis in C/
EBPb
+/+ mice but not in mice expressing C/EBPb-Ala217, a non-
phosphorylatable RSK-inhibitory transgene as detected by
morphological, semi quantitative and quantitative assays. Blocking
phosphorylation of C/EBPb-Thr217 through the inhibition of
RSK activity with the C/EBPb-Ala217 transgene or by C/EBPb
gene knock-out decreases the fibrotic response of the liver to
chronic injury. These findings indicate that the RSK phosphoac-
ceptor site in C/EBPb, which is identical in mouse and human [5],
is essential for HSC survival upon their activation in chronic liver
injury in mice. Further, the decreased fibrotic response of the liver
to the hepatotoxin in C/EBPb
2/2 mice suggests that the critical
target of RSK in activated HSC is C/EBPb-Thr217 rather than
Figure 9. Increased expression of active RSK and C/EBPb-Phos-
phoThr217 in activated hepatic stellate cells of human liver fibrosis.
Representative confocal microscopy of 4 patients with severe liver
fibrosis and 3 control subjects. A. Activated HSC, identified by confocal
microscopy for their morphology and fluorescence for glial fibrillary
acidic protein (GFAP; red), displayed activated RSK-PhosphoSer380 in
livers of patients with severe liver fibrosis (lower panel) but not in the
livers of control subjects (upper panel). Colocalization of RSK-
PhosphoSer380 and GFAP is shown in yellow (merge). Nuclei are
identified with TO-PRO-3 (blue). Only background staining was
observed when omitting the first antibody. B. C/EBPb-PhosphoThr217
(green) was present in activated HSC only in livers of patients with liver
fibrosis (lower panel). Colocalization of C/EBPb-PhosphoThr217 and
GFAP (red) is shown in yellow (merge). Nuclei are identified with TO-
PRO-3 (blue).
doi:10.1371/journal.pone.0001372.g009
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proteins [10–14].
Because liver inflammation induces liver injury and liver fibrosis
[34] we assessed the degree of liver injury and the inflammatory
response to the hepatotoxin. We found decreased liver injury and
inflammation in response to CCl4 treatment in mice expressing the
C/EBPb-Ala217 transgene. Our data suggest that in addition to
increased HSC apoptosis, partial resistance to liver injury and
inflammation may contribute to the prevention of liver fibrosis in
C/EBPb-Ala217 mice. A decreased inflammatory response,
mediated at least in part by monocytes/macrophages in the livers
of C/EBPb
+/+ mice, may be responsible for the decreased liver
injury in C/EBPb-Ala217 mice, since RSK inhibition also affected
the recruitment of CD-68+ inflammatory cells to the liver. Our
results are congruent with the proposed role of macrophages as a
major contributor to liver injury and liver fibrosis [20] [22].
Similarly to our findings of RSK inhibition in cell-free, cultured
primary stellate cells and in C/EBPb-Ala217 transgenicmice,thecell
permeant Ac-KAla217VD-CHO peptide prevented the phosphory-
lation of C/EBPb on Thr217 in HSC activated by the liver injury
induced by CCl4. Further, and in agreement to our findings of the
increased caspase 8 activation in cell-free, cultured primary stellate
cells and in C/EBPb-A217 transgenic mice, the Ac-KAla217VD-
CHO peptide stimulated the apoptotic pathway of C/EBPb
+/+ HSC
as indicated by the presence of active caspase 8 and 3.
C/EBPb
+/+ mice with severe liver fibrosis induced by an 8-week
CCl4 treatment, while continuing on CCl4, were treated with the
cell permeant RSK-inhibitory peptide for 4 or 8 weeks. The
peptide inhibited RSK activation, stimulated apoptosis of HSC
and blocked active fibrogenesis, preventing progression and
inducing regression of liver fibrosis compared to control mice
treated with CCl4. Because the resulting activation of HSC and
liver fibrosis is similar in any type of chronic liver injury, these
results suggest that the inhibition of both RSK and its
phosphorylation of C/EBPb may be effective in preventing/
regressing liver fibrosis in animal models that reflect other causes
of human liver fibrosis, such as biliary cirrhosis, alcoholic liver
disease, immune liver injury, and genetic iron overload [3].
To assess the relevance of the cellular and animal models of liver
fibrosis to human liver fibrosis, we analyzed, in preliminary
studies, the role of activated RSK and phosphorylated C/EBPb on
Thr266 (identical to mouse Thr217 phosphoacceptor) as possible
mechanisms leading to increased liver fibrosis. Liver biopsies from
hepatitis C patients afflicted with severe liver fibrosis displayed a
high level expression of both active, phosphorylated RSK and
phosphorylated human C/EBPb on Thr266 in activated HSC
within the fibrous tissue, compared with samples from control
patients. Thus, our findings in liver biopsies from patients with
liver fibrosis are congruent with the hypothesis we developed in
cell-free, cellular and animal models implicating RSK activation
and its phosphorylation of C/EBPb in activated HSC in the
development of human liver fibrosis.
Clinical Implications
Our data indicate that the RSK-C/EBPb phosphorylation
pathway in HSC is activated in severe human liver fibrosis, and
that it is critical for the progression of liver injury to severe liver
fibrosis and cirrhosis in an animal model.
This study suggest that blocking RSK activity inhibits
fibrogenesis directly by inducing HSC apoptosis, and indirectly,
by reducing liver injury and inflammation. There is no available
treatment for liver fibrosis. We speculate that these findings may
facilitate the development of small molecules potentially useful in
the prevention and treatment of liver fibrosis.
Both regression of liver fibrosis as well as lack of progression of
liver fibrosis, in spite of continued liver injury, as we clearly
documented in our study, are considered important clinical targets
for patients with chronic liver disease and liver fibrosis [34].
Finally, blocking the progression of liver fibrosis would decrease
development of primary liver cancer in these patients since the
majority of hepatocellular carcinomas arise in cirrhotic livers [39].
MATERIAL AND METHODS
Construction of C/EBPb-Ala217 mice
The Animal Protocol was approved by the VA Healthcare Center’s
Veterinarian Medical Unit. Transgenic mice expressing C/EBPb-
Ala217, a dominant negative, nonphosphorylatable mutation of the
C/EBPb-Thr217 phosphoacceptor, were generated as described
previously [10] and back-crossed to the parental wild-type inbreed
FVB mice for .4 generations. The mouse C/EBPb cDNA was
amplified by PCR to mutate Thr217. The primers used to mutate
Thr217 to Ala217 were S 59-GCC AAG GCC AAG AAG GCG
GTG GAC AAG CTG AGC -39and AS 59-GCT CAG CTT GTC
CAC CGC CTT CTT GGC CTT GGC -39.C / E B P b was
removed from pEVRF0 with Apa I and Nhe I and cloned into
pHM6 vector (Boehringer-Mannheim, cat. # 1814664) in order to
add an RSV promoter upstream to the C/EBPb start site. C/EBPb
was removed from this new construct with Bsa I and Bsp. The 982
bp insert was cloned into mammalian vector pOP13CAT
(Stratagene) from which the CAT portion had been previously
removed. DNA for pronuclear injection was purified over a CsCl
gradient and digested with Ssp I and EclHK I. The 3.6 Kb fragment
was separated on gel electrophoresis on a 0.8% gel with no Ethidium
Bromide. The appropriate band was removed and electro eluted
from the gel using the Elutrap apparatus from Schleicher & Schuell.
The eluted DNA was purified with a Qiagen-20 column,
precipitated with isopropanol and dissolved in 7.5 mM TRIS
pH 7.4, 0.15 mM EDTA. All solutions were prepared with tissue
grade water,endotoxintested (Gibco).Finally theDNA wasdialyzed
and injected into fertilized ova at a concentration of 1.8 mg/ml, at
the Transgenic Mouse Core Facilities, University of California, San
Diego. The presence of the rsv gene was used to identify these
transgenic mice by PCR, and 3 positive mice resulted. The primer
sequences for the RSV PCR were custom designed (RSV.2271
TAGGGTGTGTTTAGGCGAAA sense and RSV.2510 TCTG-
TTGCCTTCCTAATAAG antisense). The PCR reagents were all
from Qiagen. Transgene-bearing founder mice were mated with
FVB mice. All founder mice produced viable offspring. This line was
bred by mating transgene-positive mice with wild-type FVB and
backcrossed to FVB for at least four generations.
Animal Procedures
In the chronic exposure to the hepatotoxin, C/EBPb
+/+,C /
EBPbAla217 and C/EBPb
2/2 mice [10] [40] (23–27 g) each
received intraperitoneal injections of CCl4 or mineral oil (50 ml) only
once or weekly (for up to 16 weeks). In other chronic experiments,
C/EBPb
+/+ mice (25 g) each received intraperitoneal injections of
CCl4 or mineral oil (50 ml) weekly (for up to 16 weeks), but after
8 weeks, animals received either saline (control) or the cell permeant
Ac-KAla217VD-CHO (American Peptide) [10] (5 mg IP, three
times/week, for week 9, followed by 1 mg IP, three times/week for
weeks 10–12 or 10–16) while continuing to induce liver injury and
fibrosis with CCl4. In the chronic experiments, animals were
sacrificed 24 hr after the last CCl4 injection
In the acute exposure to the hepatotoxin, animals received the
cell permeant Ac-KAla217VD-CHO [10] (100 mg intraperitone-
ally) at 18 hr and animals were sacrificed at 24 hr [41].
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Adult C/EBPb
+/+ and C/EBPb-Ala217 transgenic mice were
used for the isolation of hepatic stellate cells as described [5][10].
Stellate cells were prepared, by in situ perfusion and single-step
density Nycodenz gradient (Accurate Chemical & Scientific Corp.,
Westbury, New York), as described previously [6]. Stellate cells
were identified by their typical autofluorescence at 328nm
excitation wavelength, staining of lipid droplets by oil red, and
immunohistochemistry with a monoclonal antibody against
desmin. Greater than 95% of the isolated cells were stellate cells.
Primary mouse stellate cells freshly isolated from C/EBPb
+/+
mice and activated by collagen type 1 matrix [6], were transfected
with vectors expressing RSK wild type, a catalytically inactive,
dominant negative RSK mutant, or C/EBPb-Ala217 together
with GFP [10]. Transfected stellate cells were selected by sorting
for GFP, and cell lysates were immunoprecipitated with C/EBPb
specific antibodies. In other experiments, stellate cells were
incubated for 24 hr with an ERK1/2 inhibitor (Calbiochem
328006) (10 mM), or the KAVD peptide (200 mM).
Microscopy
Fluorescent labels were observed using antibodies against C/
EBPb, RSKPhosphoSer380, a-SMA, PCNA (Santa Cruz Bio-
technology, Santa Cruz, California), active caspase 3 (PharMin-
gen, San Diego, California) or C/EBPb-PhosphoThr217 [10] in a
laser confocal microscope [5][10][42]. Fluorochromes utilized
were Alexa 488 and Alexa 594. At least 100 cells were analyzed
per experimental point [41]. We used TO-PRO-3 (Molecular
Probes, Eugene, Oregon) to analyze nuclear morphology. The
degree of liver fibrosis was determined by using the Mallory’s
trichrome and the Sirius red Immunohistochemistry [18][19]. The
interobserver agreement was .90%.
Liver Fibrosis
We determined the degree of liver fibrosis in coded samples. We
evaluated liver fibrosis employing the following methods: i)
microscopic morphology; ii) semi-quantitative METAVIR grading
system [18] ; iii) collagen type 1 immunofluorescence ; iv)
quantitative Sirius red collagen-binding assay as described [19] ;
v) quantitative hydroxyproline collagen content as described [43]
RT-PCR for collagen type 1; vii) RT-PCR for a-smooth muscle
actin (present in activated HSC); and viii) RT-PCR for
transforming growth factor-b (a pro-fibrotic cytokine) [4] [7] [8].
Formeasuringhydroxyproline,the liverwasexcised anda portion
was removed and weighed. Hydrolysis of 10 mg tissue/1ml of 6 M
HCl was performed at 120uC in a pressure vessel for 4 hr. Samples
were dried overnight in a vacuum desiccator, diluted to fall into the
assay sensitivity range and internal standards were prepared. The
chloramine-T reagent was prepared and 1 ml was added to each
sample. The samples were incubated for 20 minutes. One ml of
aldehyde-perchloric acid reagent was added to each sample and
incubated at 60uC for 15 minutes. Samples were cooled and
absorbance was read at 550nm for samples and standards.
Concentrations were determined from the standard curve.
RT-PCR Analysis
We isolated total RNA from control and experimental liver
samples using Trizol (Invitrogen). Samples were treated with
DNase using Turbo DNA-free (Ambion) and precipitated with
chloroform as per manufacturer’s protocol. cDNA synthesis was
performed using 250 ng of total RNA with the AffinityScript
Reverse Transcriptase (Stratagene). Specific sets of primers were
utilized for each RT-PCR amplification for collagen a1 type 1, a-
SMA and TGF-b, as described by the manufacturer (SuperArray,
Frederick, MD).
Liver Inflammation Genes
The liver expression of 86 inflammation genes was determined by
using the RT
2 Quantitative Real-Time PCR Array as described by
the manufacturer (SuperArray, Frederick, MD). Control and
experimental liver samples were analyzed together with internal
control samples for the RNA purification and amplification steps,
as well as for housekeeping genes (b glucuronidase, hypoxanthine
guanine phosphoribosyl transferase 1, heat shock protein1b,
glyceraldehyde-3-phosphate dehydrogenase, and b-actin), using
the BioRad iQ5 real-time PCR detection system (BioRad,
Hercules, CA). Isolation of total RNA, treatment with DNase,
precipitation with chloroform, and cDNA synthesis was performed
using 1 mg of total RNA as described for RT-PCR following the
manufacturer’s recommendations.
Cyp-2E1 Expression and Activity
Cyp-2E1 mRNA was measured by RT-PCR in control and
experimental liver samples as described above for RT-PCR. Cyp-
2E1 protein in liver samples was detected by western blot,
following the chemoluminescence protocol (Perkin-Elmer, Shel-
ton, Connecticut) using purified antibodies against Cyp-2E1
(Santa Cruz Biotechnology) as described below.
Cyp-2E1 activity was assessed in a cell-free system, using a
recombinant Cyp-2E1 and a specific substrate [44]. Inhibition of
Cyp-2E1 activity was achieved using diethyldithiocarbamate
(Sigma-Aldrich). We evaluated the effects of the RSK-inhibitory
Ac-KAla217VD-CHO peptide (American Peptide) on Cyp-2E1
activity as described per manufacturer (Invitrogen). The standard
curve was prepared using dilutions of the fluorescent standard.
Master-mix containing the P450 baculosomes reagent, regenera-
tion system, and reaction buffer were added to the designated well
of the reaction plate. The plate was incubated for 20 minutes at
room temperature to allow the compounds to interact with the
Cyp-2E1 in the absence of enzyme turnover. The reaction plate
was pre-read at this point to measure any auto-fluorescence. The
reaction was initiated with the addition of the reaction mixture
containing substrate and NADP. The plate was incubated for
30 minutes, and the fluorescence was measured at 400 and
460 nm. Data analysis was performed as suggested by the
manufacturer.
Immunoprecipitation and Immunoblots
Pre-cleared stellate cell lysates were incubated for 2 h with purified
C/EBPb, RSK, TRADD or caspase 8 antibodies followed by the
addition of A/G+ agarose (Santa Cruz Biotechnology) for 12 h. The
immunoprecipitation reactions each contained 500 mgo ft o t a l
protein and 2 mg antibody (or purified IgG pre-immune serum as
negative control). Immunoprecipitates were washed 3 times in
500 ml cell lysis buffer [45] and resolved by SDS-PAGE, and C/
EBPb, RSK, RSKp380, TNFR-1, TRADD, RIP, TRAF-2, b-actin
and caspase 8 detected by western blot [41][46][47], following the
chemoluminescence protocol (Perkin-Elmer, Shelton, Connecticut)
using purified antibodies against C/EBPb (C-19; aa 258-276), RSK,
RSKp380, TRADD, RIP, b-actin (Santa Cruz Biotechnology),
procaspase 8 (PharMingen) and C/EBPb-PhosphoThr217 [10].
Negative samples were performed omitting the first antibody.
Caspase Activity
Purified synthetic N-acetyl, C-aldehyde KAVD tetrapeptide
(American Peptide Company, Sunnyvale, California) were assayed
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recombinant caspase 8 (catalogue # 201-041-C005) (Alexis
Biochemicals). The sequence of caspase 8 includes S217 through
D479 cloned into an expression vector containing a 21 amino acid
linker at the N-terminus. Thus, the prodomain (first 220 amino
acids) is essentially missing. The fragment is cleaved at D385 and
the active caspase 8 is essentially identical to that identified in
apoptotic cells [48]. Caspase 8 activity was also measured in
stellate cell lysates, using recombinant caspase 8 as a standard for
activity. Caspase activity was determined by the release of the p-
nitroanaline colorimetric (Alexis Biochemicals, San Diego, Cali-
fornia) substrate for caspase 8 (catalogue # 260-045) within the
linear part of the kinetic assay [49] [50]. Active caspase 3 was
determined with specific antibodies (PharMingen).
RSK Activity
RSK activity was measured by the QTL Lightspeed assay (QTL
Biosystems; Santa Fe, New Mexico) using purified recombinant
RSK-2 (4,333 U/mg) (Upstate, New York), and staurosporine
(0.01 nM) as a control inhibitor. RSK activity was measured in the
presence or absence of Ac-KThr217VD-CHO (200 mM), Ac-
KAla217VD-CHO (200 mM), or C/EBPb216-253-Ala217
(0.25 nM) peptides.
Human Livers
We obtained anonymous, de-identified liver samples from 4
patients with chronic hepatitis C viral infection and severe liver
fibrosis (Metavir scores of 3 or 4) (53617 years) and from 3 control
subjects without liver disease (60613 years) (NDRI). The protocol
was approved by the University of California, San Diego Human
Protection Program.
Statistical Analysis
Results are expressed as mean (6SD). Either the Student-t or the
Wilcoxon Mann-Whitney tests were used to evaluate the
differences of the means between groups for parametric and
non-parametric populations, respectively, with a P value of ,0.05
as significant.
SUPPORTING INFORMATION
Table S1 C/EBPb-Ala217 mice have less liver damage after
CCl4 treatment. Animals received either mineral oil [MO] or
CCl4. Thirty hours after a single intraperitoneal dose of CCl4 C/
EBPb+/+ (n: 9) and C/EBPb2/2 (n: 9) mice had higher serum
alanine aminotransferase (ALT) levels than C/EBPb- Ala217 mice
(n: 9) (P,0.005 ). Results are representative of three independent
experiments.
Found at: doi:10.1371/journal.pone.0001372.s001 (0.02 MB
DOC)
Figure S1 Transgenic C/EBPb-Ala217 and C/EBPb+/+ mice
have similar Cyp-2E1 expression in the liver. Mice were treated
with CCl4 or control mineral oil for 24 or 72 hr as described in
Materials and methods. A. Liver Cyp-2E1 RNA as determined by
RT-PCR was comparable at baseline and after CCl4 treatment in
C/EBPb +/+ [wt] and C/EBPb-Ala217 mice (NS). B. Liver Cyp-
2E1 protein as determined by western blot was comparable at
baseline and after CCl4, treatment in C/EBPb +/+ [wt] and C/
EBPb- Ala217 mice (NS). C. Cyp-2E1 activity as determined in a
cell free system using a recombinant Cyp-2E1 protein was
comparable in the absence or presence of the RSK-inhibitory
Ac-KAVD-CHO peptide (1-1000 ng/ml). Values are expressed as
percentage of control Cyp-2E1 activity (open bars) (NS). A specific
Cyp-2E1 inhibitor was used as a positive control (closed bar).
Found at: doi:10.1371/journal.pone.0001372.s002 (0.66 MB TIF)
Figure S2 The association of C/EBPb with active caspase 8,
TNFR1, TRAF2, TRADD and RIP is induced by inhibiting RSK
in HSC. A Reciprocal TRADD immunoprecipitation of experi-
ment described in (7A) confirmed the association of unpho-
sphorylated C/EBPb with active caspase 8. b - Actin was used as
an internal control for the immunoprecipitations. B. Reciprocal
TNFR1 immunoprecipitation of experiment described in (Fig. 7B)
confirmed the association of unphosphorylated C/EBPb with
TNFR1. b- Actin was used as an internal control for the
immunoprecipitations. C. Reciprocal TRAF2 immunoprecipita-
tion of experiment described in (Fig. 7C) confirmed the association
of unphosphorylated C/EBPb with TRAF2. b- Actin was used as
an internal control for the immunoprecipitations.
Found at: doi:10.1371/journal.pone.0001372.s003 (0.56 MB TIF)
Figure S3 Primary mouse hepatocytes are refractory to the
induction of apoptosis by the RSK-inhibitory Ac-KAVD-CHO
peptide. Primary mouse hepatocytes were isolated from C/EBP b
+/+ [wt] mice as described in Materials and methods. Cells were
treated with Ac-KAVD-CHO peptide for 18 hr. Apoptosis was
measured by the annexin-V binding assay as described in
Materials and methods. The peptide did not induce hepatocyte
apoptosis when compared to control hepatocytes (NS).
Found at: doi:10.1371/journal.pone.0001372.s004 (0.18 MB TIF)
Figure S4 The RSK-inhibitory peptide blocks liver fibrosis
induced by CCl4. Mice were from the experiment described in
(Fig 8E and F). Representative Sirius red immunohistochemistry
for collagen (in red; arrowhead). Marked increase in liver collagen
in a cirrhotic pattern was observed in C/EBPb +/+ treated with
CCl4 but not in animals receiving the RSK-inbitory peptide.
Found at: doi:10.1371/journal.pone.0001372.s005 (0.18 MB TIF)
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